CoChat

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial

Abdelmalek, Manal, Choi, Jaeduk, Kim, Youngmin, Seo, Kyounghee, Hompesch, Marcus, Baek, Seungjae · 2020 · Journal of Hepatology

The DOI matches its Crossref record.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(20)30765-0

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 30

Metadata

Authors
Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-08
Volume
73
Pages
S124
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4233941527
Cited by
30
References
0
Citations by year
2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 1
FWCI
2.52
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
Journal of Hepatology (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
non-alcoholic fatty liver disease, liver fat reduction, weight loss, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0168-8278(20)30765-0
The paper
Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S. (2020). HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(20)30765-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.